Ascend Laboratories, LLC recalls Dabigatran etexilate Capsules
- Published
- 29 Jul 2026
- Units affected
- 2 products
- Agency
- FDA
- Country
- United States
The hazard
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.
Classification: Class III — this product is unlikely to cause health problems but breaks FDA rules (for example labeling).
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Dabigatran etexilate Capsules, 150 mg, 20-count carton (2x10), Rx only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7255-10.
Dabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7254-68.
- Brand / company
- Ascend Laboratories, LLC
- Codes / lots
- Lot: 25141584, Exp 4/30/2027. | Lot: 25141707, Exp 4/30/2027.
- Distribution
- USA Nationwide
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 29 Jul 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.